15.36
0.00%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Beijing Luzhu Biotechnology Co
Its shares trade on HKEX under the ticker 2480.HK. It has been listed since 8 May 2023.
Beijing Luzhu Biotechnology Co., Ltd. engages in the development, production, and sale of active pharmaceutical ingredients. The company is headquartered in Beijing, Beijing. The company went IPO on 2023-05-08. The firm is also engaged in out-licensing human vaccines and therapeutic biologics. Its products under clinical development include recombinant herpes zoster vaccine LZ901, and antibody injection products K3 and K193. Its LZ901 is mainly used to prevent herpes zoster caused by varicella zoster virus in adults aged 50 and above. The firm operates in the domestic market and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 May 2023
- Employees
- 129
- Website
- luzhubiotech.com ↗
Leadership
Pay as last reported
- Mr. Jian KongExecutive Chairman of the Board, General Manager, since 2002CN¥39.9m
- Ms. Xianmin JiangExecutive Vice Chairman of the Board, Deputy General Manager, since 2002CN¥7.6m
- Mr. Hui ZhangChief Financial Officer, Head - Global Capital Markets
- Ms. Ling PengChief Technology Officer, Supervisor
- Ms. Yanping ZhangDeputy General Manager, Executive DirectorCN¥31.2m
- Mr. Chaowei HanHead - Manufacturing and Engineering, Deputy General Manager of Zhuhai Luzhu
- Ms. Lijuan JiangDeputy General Manager of Zhuhai Luzhu
- Ms. Lu LuDeputy General Manager of Zhuhai Luzhu
- Mr. Siyu LiuJoint Company Secretary, Secretary of Board
- Ms. Wing Yan YuenJoint Company Secretary
- Mr. Shuangquan KongNon-Executive Director
- Mr. Biao MaNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Beijing Luzhu Biotechnology develops active pharmaceutical ingredients with 129 employees.
- LZ901 recombinant herpes zoster vaccine targets adults 50+ for varicella zoster prevention.
- The company operates in domestic and overseas markets for biologics and vaccines.
Weaknesses
- The company has no products in commercial production yet.
- Beijing Luzhu Biotechnology has only one clinical stage product LZ901.
- Its out-licensing activities for human vaccines are limited to current development stage.
Opportunities
- The global biotechnology market offers growth for recombinant vaccines like LZ901.
- Overseas markets provide expansion opportunities for therapeutic biologics K3 and K193.
- Domestic market demand for herpes zoster vaccines is increasing in China.
Threats
- The biotechnology sector faces regulatory challenges for new drug approvals.
- Competition in the vaccine market may intensify with new entrants.
- Clinical development delays could impact product launch timelines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.